Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Lion

Showing results (21-30 of 68) with videos related to

Pageof 7
Sort By:
Cancer Immunology, Immunotherapy : CII|May 19, 2009
The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cellsEvelien L J M Smits, Nathalie Cools, Eva Lion, et al.
Journal of Translational Medicine|March 15, 2022
Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cellsGils Roex, Diana Campillo-Davo, Donovan Flumens, et al.
Frontiers in Immunology|March 31, 2018
Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat CancerMaarten Versteven, Johan M J Van den Bergh, Elly Marcq, et al.
Oncotarget|November 23, 2017
Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patientsElly Marcq, Jorrit De Waele, Jonas Van Audenaerde, et al.
Journal of Hematology & Oncology|December 4, 2020
Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myelomaGils Roex, Marijke Timmers, Kristien Wouters, et al.
Cancers|September 25, 2019
Dendritic Cell-Based and Other Vaccination Strategies for Pediatric CancerSévérine de Bruijn, Sébastien Anguille, Joris Verlooy, et al.
Human Vaccines & Immunotherapeutics|June 20, 2013
Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapySébastien Anguille, Eva Lion, Johan Van den Bergh, et al.
Pharmaceutics|April 3, 2021
The Ins and Outs of Messenger RNA Electroporation for Physical Gene Delivery in Immune Cell-Based TherapyDiana Campillo-Davo, Maxime De Laere, Gils Roex, et al.
Cancers|June 26, 2019
Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic AgentKatrijn Broos, Quentin Lecocq, Catarina Xavier, et al.
Journal of Hematology & Oncology|October 1, 2016
Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cellsHeleen H Van Acker, Sébastien Anguille, Yannick Willemen, et al.
Pageof 7

Showing results (21-30 of 68) with videos related to

Sort By:
Pageof 7
Cancer Immunology, Immunotherapy : CII|May 19, 2009
The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cellsEvelien L J M Smits, Nathalie Cools, Eva Lion, et al.
Journal of Translational Medicine|March 15, 2022
Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cellsGils Roex, Diana Campillo-Davo, Donovan Flumens, et al.
Frontiers in Immunology|March 31, 2018
Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat CancerMaarten Versteven, Johan M J Van den Bergh, Elly Marcq, et al.
Oncotarget|November 23, 2017
Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patientsElly Marcq, Jorrit De Waele, Jonas Van Audenaerde, et al.
Journal of Hematology & Oncology|December 4, 2020
Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myelomaGils Roex, Marijke Timmers, Kristien Wouters, et al.
Cancers|September 25, 2019
Dendritic Cell-Based and Other Vaccination Strategies for Pediatric CancerSévérine de Bruijn, Sébastien Anguille, Joris Verlooy, et al.
Human Vaccines & Immunotherapeutics|June 20, 2013
Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapySébastien Anguille, Eva Lion, Johan Van den Bergh, et al.
Pharmaceutics|April 3, 2021
The Ins and Outs of Messenger RNA Electroporation for Physical Gene Delivery in Immune Cell-Based TherapyDiana Campillo-Davo, Maxime De Laere, Gils Roex, et al.
Cancers|June 26, 2019
Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic AgentKatrijn Broos, Quentin Lecocq, Catarina Xavier, et al.
Journal of Hematology & Oncology|October 1, 2016
Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cellsHeleen H Van Acker, Sébastien Anguille, Yannick Willemen, et al.
Pageof 7